Second International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions)

Publication

Second International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions)

Journal Paper/Review - Nov 30, 2018

Rageth Christoph J, Morris Elisabeth, Boos Andreas, Sonnenschein Martin, Malhaire Caroline, Knauer Michael, Dellas Sophie, Foschini Maria P, Fallenberg Eva Maria, Baltzer Pascal A, Dammann Florian, Tausch Christoph, Decker Thomas, Mundinger Alexander, Kubik-Huch Rahel A, Pinker Katja, O'Flynn Elizabeth A M, Varga Zsuzsanna

Citation

Rageth C, Morris E, Boos A, Sonnenschein M, Malhaire C, Knauer M, Dellas S, Foschini M, Fallenberg E, Baltzer P, Dammann F, Tausch C, Decker T, Mundinger A, Kubik-Huch R, Pinker K, O'Flynn E, Varga Z. Second International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions). Breast Cancer Res Treat 2018

Type

Journal Paper/Review (English)

Journal

Breast Cancer Res Treat 2018

Publication Date

Nov 30, 2018

Issn Electronic

1573-7217

Brief description/objective

PURPOSE
The second International Consensus Conference on B3 lesions was held in Zurich, Switzerland, in March 2018, organized by the International Breast Ultrasound School to re-evaluate the consensus recommendations.

METHODS
This study (1) evaluated how management recommendations of the first Zurich Consensus Conference of 2016 on B3 lesions had influenced daily practice and (2) reviewed current literature towards recommendations to biopsy.

RESULTS
In 2018, the consensus recommendations for management of B3 lesions remained almost unchanged: For flat epithelial atypia (FEA), classical lobular neoplasia (LN), papillary lesions (PL) and radial scars (RS) diagnosed on core-needle biopsy (CNB) or vacuum-assisted biopsy (VAB), excision by VAB in preference to open surgery, and for atypical ductal hyperplasia (ADH) and phyllodes tumors (PT) diagnosed at VAB or CNB, first-line open surgical excision (OE) with follow-up surveillance imaging for 5 years. Analyzing the Database of the Swiss Minimally Invasive Breast Biopsies (MIBB) with more than 30,000 procedures recorded, there was a significant increase in recommending more frequent surveillance of LN [65% in 2018 vs. 51% in 2016 (p = 0.004)], FEA (72% in 2018 vs. 62% in 2016 (p = 0.005)), and PL [(76% in 2018 vs. 70% in 2016 (p = 0.04)] diagnosed on VAB. A trend to more frequent surveillance was also noted also for RS [77% in 2018 vs. 67% in 2016 (p = 0.07)].

CONCLUSIONS
Minimally invasive management of B3 lesions (except ADH and PT) with VAB continues to be appropriate as an alternative to first-line OE in most cases, but with more frequent surveillance, especially for LN.